Scandion Oncology’s candidate SCO-101 is being developed to fight resistance to cancer drugs. The novel mechanism of action makes SCO-101 a First-in-Class candidate, something that has not gone unnoticed in the pharma industry. BioStock reached out to Scandion’s CEO Nils Brünner for a briefing on the company’s accomplishments so far this year and how SCO-101 will be positioned as an innovative compound within a combination regimen for combatting drug resistance.
Läs hela intervjun med Scandion Oncologys vd Nils Brünner på biostock.se:
https://www.biostock.se/2019/11/scandion-oncology-ceo-sco-101-promises-blockbuster-potential/
Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se
